Small but mighty: Platelets as central effectors of host defense

Thrombosis and Haemostasis

Volumn 117, Issue 4, 2017, Pages 651-661

  Stocker, Thomas J ^a   Ishikawa Ankerhold, Hellen ^a   Massberg, Steffen ^a,b   Schulz, Christian ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Inflammation; Leukocyte function activation; Platelet immunology; Platelet physiology; Sepsis

Indexed keywords

ACTIN; B7 ANTIGEN; BETA DEFENSIN; CD11B ANTIGEN; CD18 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; FC RECEPTOR IIA; FIBRIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; KINOCIDIN; LEUKOCYTE ELASTASE; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MEMBRANE PROTEIN; MYELOPEROXIDASE; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PENTRAXIN; PROSTAGLANDIN E2; THROMBOCIDIN; THROMBOCYTE FACTOR 4; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; AUTACOID; PATTERN RECOGNITION RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; EXTRACELLULAR TRAP; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOTHROMBOSIS; INFECTION; INFLAMMATION; INTRACELLULAR SIGNALING; KUPFFER CELL; MACROPHAGE; NONHUMAN; PATHOGEN CLEARANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEPSIS; TH17 CELL; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS; TISSUE REPAIR; ANIMAL; BLOOD; HEMOSTASIS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; WOUND HEALING;

ANIMALS; BLOOD PLATELETS; HEMOSTASIS; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PLATELET ACTIVATION; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 85019380519     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-12-0921     Document Type: Review

References (182)

1. Semple JW, et al. Platelets and the immune continuum. Nat Rev Immunol 2011; 11: 264-274.
2. Morrell CN, et al. Emerging roles for platelets as immune and inflammatory cells. Blood 2014; 123: 2759-2767.
3. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
4. Boilard E, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010; 327: 580-583.
5. Khan SY, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006; 108: 2455-2462.
6. Smyth SS, et al. Platelet functions beyond haemostasis. J Thromb Haemost 2009; 7: 1759-1766.
7. Cox D, et al. Platelets and the innate immune system: mechanisms of bacterialinduced platelet activation. J Thromb Haemost 2011; 9: 1097-1107.
8. Lam FW, et al. Platelets and Their Interactions with Other Immune Cells. Compr Physiol 2015; 5: 1265-1280.
9. Gros A, et al. Platelets in inflammation: regulation of leukocyte activities and vascular repair. Front Immunol 2014; 5: 678.
10. Lindemann S, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154: 485-490.
11. Zuchtriegel G, et al. Platelets Guide Leukocytes to Their Sites of Extravasation. PLoS Biol 2016; 14: e1002459.
12. Weyrich AS. Platelets: more than a sack of glue. Hematology Am Soc Hematol Educ Program 2014; 2014: 400-403.
13. Hartwig H, et al. Platelet-derived PF4 reduces neutrophil apoptosis following arterial occlusion. Thromb Haemost 2014; 111: 562-564.
14. Scheuerer B, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000; 95: 1158-1166.
15. Peerschke EI, et al. Platelet activation by C1q results in the induction of alpha IIb/beta 3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity. J Exp Med 1993; 178: 579-587.
16. Nguyen T, et al. Staphylococcus aureus protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets. Infect Immun 2000; 68: 2061-2068.
17. Riaz AH, et al. Human platelets efficiently kill IgG-opsonized E. coli. FEMS Immunol Med Microbiol 2012; 65: 78-83.
18. von Hundelshausen P, et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105: 924-930.
19. Brandt E, et al. The beta-thromboglobulins and platelet factor 4: blood plateletderived CXC chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol 2000; 67: 471-478.
20. Shiraki R, et al. Expression of Toll-like receptors on human platelets. Thromb Res 2004; 113: 379-385.
21. von Hundelshausen P, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-1777.
22. Mei J, et al. CXCL5 regulates chemokine scavenging and pulmonary host defense to bacterial infection. Immunity 2010; 33: 106-117.
23. Zarbock A, et al. Platelet-neutrophil-interactions: linking haemostasis and inflammation. Blood Rev 2007; 21: 99-111.
24. Moore KL, et al. Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. J Cell Biol 1992; 118: 445-456.
25. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13: 34-45.
26. Schulz C, et al. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol 2008; 103: 356-367.
27. Assoian RK, et al. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 1983; 258: 7155-7160.
28. Lievens D, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010; 116: 4317-4327.
29. Stark K, et al. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood 2016; Epub ahead of print.
30. Bennett JS. Structure and function of the platelet integrin alphaIIbbeta3. J Clin Invest 2005; 115: 3363-3369.
31. Jin DK, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nature Med 2006; 12: 557-567.
32. Diacovo TG, et al. A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J Clin Invest 1994; 94: 1243-1251.
33. Kraemer BF, et al. Novel anti-bacterial activities of beta-defensin 1 in human platelets: suppression of pathogen growth and signaling of neutrophil extracellular trap formation. PLoS Pathog 2011; 7: e1002355.
34. Youssefian T, et al. Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. Blood 2002; 99: 4021-4029.
35. Krijgsveld J, et al. Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J Biol Chem 2000; 275: 20374-20381.
36. Yeaman MR, et al. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J Clin Invest 1998; 101: 178-187.
37. Yeaman MR, et al. Purification and in vitro activities of rabbit platelet microbicidal proteins. Infect Immun 1997; 65: 1023-1031.
38. Cole AM, et al. Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. J Immunol 2001; 167: 623-627.
39. Kerrigan SW, et al. A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation. Blood 2002; 100: 509-516.
40. McMorran BJ, et al. Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum. Science 2012; 338: 1348-1351.
41. Aslam R, et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006; 107: 637-641.
42. Semple JW, et al. Platelet-bound lipopolysaccharide enhances Fc receptor-mediated phagocytosis of IgG-opsonized platelets. Blood 2007; 109: 4803-4805.
43. Schulz C, et al. Crossroads of coagulation and innate immunity: the case of deep vein thrombosis. J Thromb Haemost 2013; 11 (Suppl 1): 233-241.
44. Palabrica T, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-851.
45. Clark SR, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nature Med 2007; 13: 463-469.
46. Massberg S, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nature Med 2010; 16: 887-896.
47. Etulain J, et al. P-selectin promotes neutrophil extracellular trap formation in mice. Blood 2015; 126: 242-246.
48. Maugeri N, et al. Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J Thromb Haemost 2014; 12: 2074-2088.
49. Brinkmann V, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-1535.
50. Jaillon S, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007; 204: 793-804.
51. Fuchs TA, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-15885.
52. Reinhardt C, et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 2008; 118: 1110-1122.
53. Jasuja R, et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest 2012; 122: 2104-2113.
54. Cho J, et al. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest 2008; 118: 1123-1131.
55. Schulz C, et al. Identification of novel downstream targets of platelet glycoprotein VI activation by differential proteome analysis: implications for thrombus formation. Blood 2010; 115: 4102-4110.
56. Muller F, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156.
57. Smith SA, et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-908.
58. Johnson LL, et al. Fibrin-mediated protection against infection-stimulated immunopathology. J Exp Med 2003; 197: 801-806.
59. Frick IM, et al. The contact system--a novel branch of innate immunity generating antibacterial peptides. EMBO J 2006; 25: 5569-5578.
60. Yeaman MR. Platelets in defense against bacterial pathogens. Cell Mol Life Sci 2010; 67: 525-544.
61. Fitzgerald JR, et al. The interaction of bacterial pathogens with platelets. Nat Rev Microbiol 2006; 4: 445-457.
62. Mangold A, et al. Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of STsegment resolution and infarct size. Circ Res 2015; 116: 1182-1192.
63. Riegger J, et al. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. Eur Heart J 2016; 37: 1538-1549.
64. von Bruhl ML, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-835.
65. Martinod K, et al. Neutrophil elastase-deficient mice form neutrophil extracellular traps in an experimental model of deep vein thrombosis. J Thromb Haemost 2016; 14: 551-558.
66. Savchenko AS, et al. VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice. Blood 2014; 123: 141-148.
67. Wuescher LM, et al. A novel conditional platelet depletion mouse model reveals the importance of platelets in protection against Staphylococcus aureus bacteremia. J Thromb Haemost 2015; 13: 303-313.
68. McMorran BJ, et al. Platelets kill intraerythrocytic malarial parasites and mediate survival to infection. Science 2009; 323: 797-800.
69. Sullam PM, et al. Effect of thrombocytopenia on the early course of streptococcal endocarditis. J Infect Dis 1993; 168: 910-914.
70. Dankert J, et al. Platelet microbicidal activity is an important defense factor against viridans streptococcal endocarditis. J Infect Dis 2001; 184: 597-605.
71. Dankert J, et al. Involvement of bactericidal factors from thrombin-stimulated platelets in clearance of adherent viridans streptococci in experimental infective endocarditis. Infect Immun 1995; 63: 663-671.
72. Wong CH, et al. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol 2013; 14: 785-792.
73. Verschoor A, et al. A platelet-mediated system for shuttling blood-borne bacteria to CD8alpha+ dendritic cells depends on glycoprotein GPIb and complement C3. Nat Immunol 2011; 12: 1194-1201.
74. Broadley SP, et al. Dual-Track Clearance of Circulating Bacteria Balances Rapid Restoration of Blood Sterility with Induction of Adaptive Immunity. Cell Host Microbe 2016; 20: 36-48.
75. Tisoncik JR, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012; 76: 16-32.
76. Schulte W, et al. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view. Mediators Inflamm 2013; 2013: 165974.
77. Remick DG, et al. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002; 17: 463-467.
78. Turnbull IR, et al. Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock 2004; 21: 121-125.
79. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-442.
80. Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. Front Biosci 1997; 2: d12-26.
81. Moudgil KD, Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res 2011; 31: 695-703.
82. O’Shea JJ, et al. Cytokines and autoimmunity. Nat Rev Immunol 2002; 2: 37-45.
83. Moreau D, et al. Platelet count decline: an early prognostic marker in critically ill patients with prolonged ICU stays. Chest 2007; 131: 1735-1741.
84. Sharma B, et al. Thrombocytopenia in septic shock patients--a prospective observational study of incidence, risk factors and correlation with clinical outcome. Anaesth Intensive Care 2007; 35: 874-880.
85. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
86. Rittirsch D, et al. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8: 776-787.
87. Goerge T, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood 2008; 111: 4958-4964.
88. Loria GD, et al. Platelets support a protective immune response to LCMV by preventing splenic necrosis. Blood 2013; 121: 940-950.
89. Xiang B, et al. Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun 2013; 4: 2657.
90. Corken A, et al. Platelet glycoprotein Ib-IX as a regulator of systemic inflammation. Arterioscler Thromb Vasc Biol 2014; 34: 996-1001.
91. Badimon L, et al. Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis. Front Pharmacol 2016; 7: 293.
92. Gudbrandsdottir S, et al. Activated platelets enhance IL-10 secretion and reduce TNF-alpha secretion by monocytes. J Immunol 2013; 191: 4059-4067.
93. Sadallah S, et al. Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. J Immunol 2011; 186: 6543-6552.
94. Ando Y, et al. Platelets attenuate production of cytokines and nitric oxide by macrophages in response to bacterial endotoxin. Platelets 2016; 27: 344-350.
95. Looney MR, et al. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009; 119: 3450-3461.
96. Yin H, et al. Role for platelet glycoprotein Ib-IX and effects of its inhibition in endotoxemia-induced thrombosis, thrombocytopenia, and mortality. Arterioscler Thromb Vasc Biol 2013; 33: 2529-2537.
97. Schauer C, et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nature Med 2014; 20: 511-517.
98. Sadallah S, et al. Ectosomes released by platelets induce differentiation of CD4+T cells into T regulatory cells. Thromb Haemost 2014; 112: 1219-1229.
99. Shi G, et al. Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection. J Clin Invest 2014; 124: 543-552.
100. Chakraverty R. An unexpected role for platelets in blocking Th17 differentiation. J Clin Invest 2014; 124: 480-482.
101. Dinkla S, et al. Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin. Blood 2016; 127: 1976-1986.
102. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010; 10: 849-859.
103. Fontenot JD, et al. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
104. Dominguez-Villar M, et al. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nature Med 2011; 17: 673-675.
105. Ueno A, et al. Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis 2013; 19: 2522-2534.
106. Bovenschen HJ, et al. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 2011; 131: 1853-1860.
107. Crist SA, et al. Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes. Blood 2008; 111: 3553-3561.
108. Beaulieu LM, et al. Interleukin 1 receptor 1 and interleukin 1beta regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans. Arterioscler Thromb Vasc Biol 2014; 34: 552-564.
109. D’Atri LP, et al. Expression and functionality of Toll-like receptor 3 in the megakaryocytic lineage. J Thromb Haemost 2015; 13: 839-850.
110. Beaulieu LM, et al. Regulatory effects of TLR2 on megakaryocytic cell function. Blood 2011; 117: 5963-5974.
111. Rondina MT, Weyrich AS. Regulation of the genetic code in megakaryocytes and platelets. J Thromb Haemost 2015; 13 (Suppl 1): S26-32.
112. Laffont B, et al. Activated platelets can deliver mRNA regulatory Ago2*microRNA complexes to endothelial cells via microparticles. Blood 2013; 122: 253-261.
113. Risitano A, et al. Platelets and platelet-like particles mediate intercellular RNA transfer. Blood 2012; 119: 6288-6295.
114. Serhan CN, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007; 21: 325-332.
115. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014; 510: 92-101.
116. Serhan CN, et al. Resolving inflammation: dual anti-inflammatory and proresolution lipid mediators. Nat Rev Immunol 2008; 8: 349-361.
117. Hoffmann PR, et al. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J Immunol 2005; 174: 1393-1404.
118. Huynh ML, et al. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002; 109: 41-50.
119. Li MO, et al. Phosphatidylserine receptor is required for clearance of apoptotic cells. Science 2003; 302: 1560-1563.
120. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005; 6: 1191-1197.
121. Buckley CD, et al. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 2014; 40: 315-327.
122. Serhan CN, et al. Lipid mediators in the resolution of inflammation. Cold Spring Harb Perspect Biol 2015; 7: a016311.
123. Norling LV, Serhan CN. Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. J Intern Med 2010; 268: 15-24.
124. Perretti M, D’Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009; 9: 62-70.
125. Dalli J, et al. Proresolving and tissue-protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide receptor 2/lipoxin A4 receptor. J Immunol 2013; 190: 6478-6487.
126. Wallace JL, et al. Gaseous mediators in resolution of inflammation. Semin Immunol 2015; 27: 227-233.
127. Caliendo G, et al. Synthesis and biological effects of hydrogen sulfide (H2S): development of H2S-releasing drugs as pharmaceuticals. J Med Chem 2010; 53: 6275-6286.
128. Dalli J, et al. The Regulation of Proresolving Lipid Mediator Profiles in Baboon Pneumonia by Inhaled Carbon Monoxide. Am J Respir Cell Mol Biol 2015; 53: 314-325.
129. Chiang N, et al. Inhaled carbon monoxide accelerates resolution of inflammation via unique proresolving mediator-heme oxygenase-1 circuits. J Immunol 2013; 190: 6378-6388.
130. Hasko G, Cronstein B. Regulation of inflammation by adenosine. Front Immunol 2013; 4: 85.
131. Koroskenyi K, et al. Involvement of adenosine A2A receptors in engulfmentdependent apoptotic cell suppression of inflammation. J Immunol 2011; 186: 7144-7155.
132. Csoka B, et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J 2012; 26: 376-386.
133. Mirakaj V, et al. Vagus nerve controls resolution and pro-resolving mediators of inflammation. The Journal of experimental medicine 2014; 211: 1037-1048.
134. Pavlov VA, Tracey KJ. The vagus nerve and the inflammatory reflex--linking immunity and metabolism. Nat Rev Endocrinol 2012; 8: 743-754.
135. Basil MC, Levy BD. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat Rev Immunol 2016; 16: 51-67.
136. Romano M, Serhan CN. Lipoxin generation by permeabilized human platelets. Biochemistry 1992; 31: 8269-8277.
137. Fiore S, Serhan CN. Formation of lipoxins and leukotrienes during receptormediated interactions of human platelets and recombinant human granulocyte/ macrophage colony-stimulating factor-primed neutrophils. J Exp Med 1990; 172: 1451-1457.
138. Serhan CN, Sheppard KA. Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J Clin Invest 1990; 85: 772-780.
139. Tang K, et al. Microparticles mediate enzyme transfer from platelets to mast cells: a new pathway for lipoxin A4 biosynthesis. Biochem Biophys Res Commun 2010; 400: 432-436.
140. Godson C, et al. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 2000; 164: 1663-1667.
141. Abdulnour RE, et al. Maresin 1 biosynthesis during platelet-neutrophil interactions is organ-protective. Proc Natl Acad Sci USA 2014; 111: 16526-16531.
142. Gong J, et al. Maresin 1 mitigates LPS-induced acute lung injury in mice. Br J Pharmacol 2014; 171: 3539-3550.
143. Hong S, et al. Maresin-like lipid mediators are produced by leukocytes and platelets and rescue reparative function of diabetes-impaired macrophages. Chem Biol 2014; 21: 1318-1329.
144. Eldering JA, et al. Presence of lipocortins I and IV, but not II and VI, in human platelets. FEBS Lett 1993; 318: 231-234.
145. Murphy CT, et al. Evidence for the presence and location of annexins in human platelets. Biochem Biophys Res Commun 1992; 189: 1739-1746.
146. Walther A, et al. A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. Mol Cell 2000; 5: 831-840.
147. Zouki C, et al. The anti-inflammatory peptides, antiflammins, regulate the expression of adhesion molecules on human leukocytes and prevent neutrophil adhesion to endothelial cells. FASEB J 2000; 14: 572-580.
148. Fredman G, Serhan CN. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem J 2011; 437: 185-197.
149. Akbiyik F, et al. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004; 104: 1361-1368.
150. Croasdell A, et al. PPARgamma and the Innate Immune System Mediate the Resolution of Inflammation. PPAR Res 2015; 2015: 549691.
151. Sidhu JS, et al. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 2004; 147: e25.
152. Rao F, et al. PPARgamma ligands decrease hydrostatic pressure-induced platelet aggregation and proinflammatory activity. PloS one 2014; 9: e89654.
153. Chu CS, et al. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2006; 97: 646-650.
154. Ray DM, et al. Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. Thromb Haemost 2008; 99: 86-95.
155. Gurtner GC, et al. Wound repair and regeneration. Nature 2008; 453: 314-321.
156. Langer HF, et al. Platelet derived bFGF mediates vascular integrative mechanisms of mesenchymal stem cells in vitro. J Mol Cell Cardiol 2009; 47: 315-325.
157. Crowley ST, et al. Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation 1994; 90: 1908-1918.
158. Walsh TG, et al. The functional role of platelets in the regulation of angiogenesis. Platelets 2015; 26: 199-211.
159. Chandraratne S, et al. Critical role of platelet glycoprotein ibalpha in arterial remodeling. Arterioscler Thromb Vasc Biol 2015; 35: 589-597.
160. Stellos K, et al. Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 2008; 117: 206-215.
161. Massberg S, et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med 2006; 203: 1221-1233.
162. Bermudez DM, et al. Inhibition of stromal cell-derived factor-1alpha further impairs diabetic wound healing. J Vasc Surg 2011; 53: 774-784.
163. Barrientos S, et al. Growth factors and cytokines in wound healing. Wound Repair Regen 2008; 16: 585-601.
164. Li L, et al. PDGF-induced proliferation in human arterial and venous smooth muscle cells: molecular basis for differential effects of PDGF isoforms. J Cell Biochem 2011; 112: 289-298.
165. Lindahl P, et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277: 242-245.
166. Battinelli EM, et al. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 2011; 118: 1359-1369.
167. Mehta VB, Besner GE. HB-EGF promotes angiogenesis in endothelial cells via PI3-kinase and MAPK signaling pathways. Growth Factors 2007; 25: 253-263.
168. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 (Suppl 1): S13-33.
169. Margolis DJ, et al. Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen 2000; 8: 480-493.
170. Golebiewska EM, Poole AW. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev 2015; 29: 153-162.
171. Embil JM, et al. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy. Wound Repair Regen 2000; 8: 162-168.
172. Ollivier V, et al. Collagen can selectively trigger a platelet secretory phenotype via glycoprotein VI. PloS one 2014; 9: e104712.
173. Milioli M, et al. Quantitative proteomics analysis of platelet-derived microparticles reveals distinct protein signatures when stimulated by different physiological agonists. J Proteomics 2015; 121: 56-66.
174. Velez P, et al. A 2D-DIGE-based proteomic analysis reveals differences in the platelet releasate composition when comparing thrombin and collagen stimulations. Sci Rep 2015; 5: 8198.
175. Klockenbusch C, et al. Global proteome analysis identifies active immunoproteasome subunits in human platelets. Mol Cell Proteomics 2014; 13: 3308-3319.
176. Zufferey A, et al. Characterization of the platelet granule proteome: evidence of the presence of MHC1 in alpha-granules. J Proteomics 2014; 101: 130-140.
177. Sehgal S, Storrie B. Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release. J Thromb Haemost 2007; 5: 2009-2016.
178. Chatterjee M, et al. Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli. Blood 2011; 117: 3907-3911.
179. Italiano JE, Jr., et al. Angiogenesis is regulated by a novel mechanism: pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227-1233.
180. Pokrovskaya ID, et al. STEM tomography reveals that the canalicular system and alpha-granules remain separate compartments during early secretion stages in blood platelets. J Thromb Haemost 2016; 14: 572-584.
181. Ghasemzadeh M, et al. The CXCR1/2 ligand NAP-2 promotes directed intravascular leukocyte migration through platelet thrombi. Blood 2013; 121: 4555-4566.
182. Kulkarni S, et al. Conversion of platelets from a proaggregatory to a proinflammatory adhesive phenotype: role of PAF in spatially regulating neutrophil adhesion and spreading. Blood 2007; 110: 1879-1886